Asenapine , 96% , 65576-45-6
CAS NO.:65576-45-6
Empirical Formula: C17H16ClNO
Molecular Weight: 285.772
MDL number: MFCD09838016
EINECS: 2658294
Pack Size | Price | Stock | Quantity |
25mg | RMB854.40 | In Stock |
|
100mg | RMB3299.20 | In Stock |
|
1g | RMB9075.20 | In Stock |
|
others | Enquire |
PRODUCT Properties
Boiling point: | 357.9±42.0 °C(Predicted) |
Density | 1.231 |
storage temp. | Store at +4°C |
solubility | DMSO:50.0(Max Conc. mg/mL);174.97(Max Conc. mM) |
form | A solid |
pka | 9.50±0.20(Predicted) |
color | White to off-white |
Description and Uses
(±)-Asenapine is an atypical antipsychotic. It binds to dopamine D1-4, α-adrenergic, and histamine receptors (Kis = 0.42-1.45, 0.32-1.26, and 1-6.17 nM, respectively), as well as the serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, and 5-HT7 (Kis = 0.03-3.98 nM). (±)-Asenapine inhibits the suppression of neuron firing induced by the 5-HT2A, dopamine D2, and α2-adrenergic receptor agonists 2,5-dimethoxy-4-iodoamphetamine (DOI), apomorphine, and clonidine , respectively, in rat brain (ED50s = 75, 40, and 85 μg/kg, respectively). In vivo, (±)-asenapine (0.05-0.2 mg/kg, s.c.) increases extracellular dopamine levels in the medial prefrontal cortex (mPFC), nucleus accumbens (NAc), and lateral striatum and suppresses the conditioned avoidance response in rats. It prevents acute and chronic phencyclidine-induced deficits in cued reversal learning in rats when administered at a dose of 0.075 mg/kg. Formulations containing asenapine have been used in the treatment of schizophrenia and bipolar I disorder.
Combined serotonin (5HT2) and dopamine (D2) receptor antagonist; structurally related to Mianserin. Antipsychotic
Safety
Symbol(GHS) | GHS07 |
Signal word | Warning |
Hazard statements | H319-H315-H335 |
Precautionary statements | P264-P280-P302+P352-P321-P332+P313-P362-P264-P280-P305+P351+P338-P337+P313P |
Hazardous Substances Data | 65576-45-6(Hazardous Substances Data) |